Palo Alto Investors LP Invests $2.77 Million in Stoke Therapeutics, Inc. $STOK

Posted by Brenda Bartman on Aug 28th, 2026

Palo Alto Investors LP acquired a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 84,631 shares of the company’s stock, valued at approximately $2,769,126. Palo Alto Investors LP owned about 0.13% of Stoke Therapeutics as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Stoke Therapeutics by 5.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock valued at $162,000 after purchasing an additional 1,149 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Stoke Therapeutics by 21.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after purchasing an additional 293,072 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Stoke Therapeutics by 125.2% in the first quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock valued at $179,000 after purchasing an additional 15,001 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Stoke Therapeutics by 26.6% during the second quarter. JPMorgan Chase & Co. now owns 25,655 shares of the company’s stock worth $291,000 after purchasing an additional 5,398 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Stoke Therapeutics by 33.9% during the 2nd quarter. Rhumbline Advisers now owns 66,419 shares of the company’s stock worth $754,000 after buying an additional 16,820 shares in the last quarter.

Stoke Therapeutics Trading Down 3.0%

Shares of NASDAQ STOK traded down $0.97 on Friday, reaching $31.62. 754,095 shares of the company traded hands, compared to its average volume of 764,425. Stoke Therapeutics, Inc. has a fifty-two week low of $18.80 and a fifty-two week high of $40.22. The stock has a market capitalization of $2.04 billion, a PE ratio of -9.47 and a beta of 1.20. The company has a 50 day moving average of $31.21 and a 200 day moving average of $32.26.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The business had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. As a group, research analysts expect that Stoke Therapeutics, Inc. will post -3.52 earnings per share for the current year.

Insider Activity

In other news, Director Edward M. Md Kaye sold 12,567 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $402,521.01. Following the completion of the sale, the director directly owned 124,557 shares of the company’s stock, valued at approximately $3,989,560.71. The trade was a 9.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 7,176 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $29.04, for a total value of $208,391.04. Following the sale, the insider owned 20,422 shares of the company’s stock, valued at $593,054.88. This represents a 26.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 30,623 shares of company stock valued at $953,765 over the last ninety days. 9.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have commented on STOK. Canaccord Genuity Group reduced their target price on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. Weiss Ratings reissued a “sell (d)” rating on shares of Stoke Therapeutics in a research report on Friday, August 7th. Guggenheim reiterated a “buy” rating and set a $60.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. The Goldman Sachs Group initiated coverage on Stoke Therapeutics in a research report on Monday, July 13th. They set a “buy” rating and a $44.00 price target for the company. Finally, Wedbush increased their price objective on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $44.25.

Get Our Latest Report on STOK

Stoke Therapeutics Profile

(Free Report)

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.